Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients

There is a significant disconnect between the escalating healthcare problem of opioid use for
chronic pain, and the development of novel therapeutic strategies. A plausible strategy is to
interrupt the vicious cycle of pain, inflammation and hyperesthesia is using highly
efficacious non-opioid drugs that do not require chronic administration, such as lidocaine.
Lidocaine is FDA approved local anesthetic, class 2 antiarrhythmic with analgesic,
antihyperalgesic and anti-inflammatory properties without rewarding and addictive properties.
Intravenous lidocaine has been utilized since 1943 for a large spectrum of pain conditions.
Lidocaine also has been shown to significantly reduce circulating inflammatory cytokines
production. Investigators propose that systemic administration of lidocaine will decrease the
intensity, duration of pain in opioid dependent chronic pain patients. The long-term goal of
this proposal is to decrease opioid dependence in chronic pain patients by using lidocaine
infusion. The central hypothesis is that lidocaine infusion decreases the intensity of pain
in opioid dependent chronic pain patients.

Primary outcome: To determine the short-term effect of lidocaine infusion on the intensity of
pain in opioid dependent chronic pain patients.

Secondary outcome1: Determine the duration of pain relief after lidocaine infusion in opioid
dependent chronic pain patients. Investigators hypothesize that lidocaine infusions will have
a long lasting Visual Analog Pain (VAS) score improvement that will extend beyond the time of
infusion.

This intermediate and long-term pain relief will be demonstrated by measuring both VAS pain
scores 3 times a day for 3 weeks and by the reduction in daily opioid use by 25%.

Secondary outcome2: Determine the effect of lidocaine infusion on opioid induced
hyperalgesia. Lidocaine infusion may decrease cytokine levels both acutely after infusion as
compared to baseline, as well as at the end of 1 week after infusion.

STUDY DESIGN AND POPULATION: Forty opioid dependent patients will be randomized in a double
blind parallel placebo control study to investigate the effects of lidocaine on neuropathic
pain. Patients who meet the inclusion criteria will receive Initial laboratory work-up prior
to infusion date. Each patient will receive a Hepatic panel, CBC, and Chemistry and baseline
cytokine levels (IL1b) as well as a baseline Cold Pressor Test (CPT) and then will be
randomized to either receive lidocaine or placebo.

Study Intervention: Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a
continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours versus
saline of same volume and duration.

Duration of the study: Patient will be followed for 3 weeks after the lidocaine infusion.

Monitoring during infusion: Heart rate, blood pressure, EKG, oxygen saturation, and any
potential side effects as sedation, circumoral numbness, metallic taste in the mouth will be
continuously monitored and recorded every 15 minutes (standard monitoring and recording time
in recovery area) as well as pain scores. After completion of infusion patient will be
further monitored for another 2 hrs and then discharged after meeting standard discharge
criteria according to Aldrete scoring system.

Discharge instruction: Patients will be asked to decrease their daily opioid dose by 25%.
Patients will receive a one-week supply of a short acting opioid as a rescue medication.
Patients will be asked to use the rescue medication if pain is moderate to severe for the
first day after infusion. If no improvement in pain despite allowable short acting medication
as reported on first day post infusion follow up phone call, patient will be asked to resume
their usual long acting opioid dose. Each patient will receive a pain diary sheet where they
will record their daily visual analogue pain scores 3 times a day as well as their daily
opioid dose plus over the counter analgesic requirements as NSAIDS and acetaminophen.
Patients will follow up every week till study completion, where pain diary, over the counter
and rescue pain medications will be assessed.

Outcome Measures:

1. Visual Analog Pain (VAS) Scores

2. Serum interleukin Ib level

3. CPT

4. Daily opioid use

Subject Safety and Data Monitoring:

All subjects will be carefully assessed prior to participation in the studies, including
medical history, laboratory tests, and examination by a board-certified physician (Dr.
Kandil). Subjects with medical problems that would increase risk for participation will be
excluded from the study.

During the infusion patient's vital signs: heart rate, blood pressure, EKG, oxygen
saturation, and any potential side effects as sedation, circumoral numbness, metallic taste
in the mouth will be continuously monitored and recorded every 15 minutes as well as pain
scores.

All lidocaine/saline infusions will be supervised by Dr. Enas Kandil, an anesthesiologist.
Dr. Kandil or a nurse will be in attendance during throughout the infusion. Heart rate,
including EKG rhythm strip, will be monitored continuously throughout the infusion and blood
pressure will be obtained every 15 minutes and more frequently if indicated. If the
participants' hemodynamics (heart rate, blood pressure) change by more than 20% (typically a
consequence of cardiac arrhythmias) the infusion will be stopped. The more serious toxic
effects of lidocaine (e.g. unconsciousness, confusion, convulsions, respiratory arrest) are
preceded by numbness of the tongue, lightheadedness, visual disturbances and muscle
twitching; infusions will be terminated if the subject reports of any of these latter signs
or symptoms. A checklist of signs and symptoms will be obtained every 15 minutes. Subjects
will be observed for at least two hours (approximately one half-life of lidocaine) following
the cessation of lidocaine (or saline) infusion. Dr. Kandil must approve discharge for all
participants on the infusion study day.

Lidocaine labels carry warnings and precautions for use in patients with various cardiac
conditions, notably conduction abnormalities (e.g., heart block, QT prolongation). Cardiac
conditions will be identified by EKG, medical history and physical exam. Participants with
any medical history of cardiac disease (e.g. myocardial infarction, congestive heart failure,
cardiac arrhythmia) or an abnormal EKG (including any arrhythmia, heart block, QT
prolongation) will be excluded.

Women with a positive pregnancy test or who report unprotected heterosexual sex since their
previous menses will not receive an infusion. Women with a positive pregnancy test will be
referred for appropriate care. Subjects will be observed for at least two hours
(approximately one half-life of lidocaine) following the cessation of lidocaine (or saline)
infusion. All participants will receive a 24-hour call-in number to contact research staff in
the advent of problems.

Inclusion Criteria:

- Age 18-65 years old -Patient currently on stable dose of opioids for more than six
months period -

- Patients with Chronic uncontrolled neuropathic pain with documented pain score > or =
4 despite opioids

- Not currently abusing opioids or other illicit drugs as demonstrated by history and
negative urine toxicology screen

- Patient agrees to come to all follow up visits at 1, 2, and 3 week following infusion

- Having baseline/screening EKG

Exclusion Criteria:

- Individuals meeting DSM-V dependence criteria for alcohol, benzodiazepine, CNS
stimulant, marijuana or other drug of abuse.

- Hepatic dysfunction as determined by history and physical or clinical significant lab.

- Cardiac arrhythmias including heart block and QT prolongation as determined by history
or baseline EKG.

- Subject has inability to understand and cooperate with study procedures or provide
informed consent.

- Subject has history of intolerance or allergic reaction to lidocaine.

- Subject has history of seizures.

- Raynaud's disease

- Renal impairment as determined by clinically significant labs.

- Women of childbearing age who either have:

1. A positive pregnancy test

2. Unprotected heterosexual sex since their previous menses or;

3. Not currently using and/or willing to use a medically approved form of
contraception (e.g., birth control pill).